Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2003-06-20
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00024141
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
- Conditions
- Breast CancerLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmTesticular Germ Cell TumorUnspecified Adult Solid Tumor, Protocol SpecificUnspecified Childhood Solid Tumor, Protocol Specific
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2013-05-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 451
- Registration Number
- NCT00060255
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors
- Conditions
- Esophageal Cancer
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2011-03-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 11
- Registration Number
- NCT00060268
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-04-16
- Last Posted Date
- 2012-04-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 61
- Registration Number
- NCT00002945
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer
- Conditions
- Lymphoma
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 1
- Registration Number
- NCT00058045
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery
- Conditions
- Lung Cancer
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2011-03-08
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 21
- Registration Number
- NCT00057798
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Compassionate Use of Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Gastrointestinal Tract
- Conditions
- Graft Versus Host Disease
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2011-03-08
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 51
- Registration Number
- NCT00055666
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
- Conditions
- LeukemiaLymphomaMyelodysplastic SyndromesMyelodysplastic-Myeloproliferative Diseases
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00055653
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00054288
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT00054158
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States